From Cancer Treatment to Celiac: Teva Aims for $7 Billion in Revenue
The Israeli pharmaceutical giant presented a plan to increase revenue from original drugs, improve profitability rates, and launch one innovative drug each year. The development pipeline includes seven advanced programs with a cumulative annual sales…
Assessment
Teva is laying out a growth plan that bets heavily on its pipeline of original drugs, not just generics. With seven advanced programs carrying a combined peak sales potential above $10 billion, the company is signaling it can return to serious revenue expansion. The target of $7 billion in sales and a new innovative drug launch each year sets a high bar. Watch whether the pipeline delivers on those peak projections, because that will determine if Teva can sustain the profitability improvements it also promised.